Skip to main content
  • MedAlliance awarded the first coronary de novo DEB IDE approval, its fourth FDA IDE Approval

    10th January 2023 – SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details